// App-Quantinova.ai

1393 : PALISADE follow‐on study (ARC004): Longer‐term outcomes with AR101 oral immunotherapy for peanut allergy

Researchers

Presenter

  • Fernndez-Rivas M

Principal Investigators

  • Hourihane JO

  • Blumchen K

  • Jones SM

  • Shreffler WG

  • Du Toit G

  • Muraro A

  • Beyer K

  • Sprikkelman A

  • Smith A

  • Vickery BP

  • Adelman DC

  • Nilsson C

Medical Centers

  • Royal College of Surgeons in Ireland, Dublin, Ireland

  • University College Cork, Cork, Ireland

  • Departement for Children and Adolescent,Division for Allergy, Pneumology and Cystic Fibrosis, University Hospital Frankfurt, Frankfurt am Main, Germany

  • University of Arkansas for Medical Sciences and Arkansas Childrens Hospital, Little Rock, United States

  • Massachusetts General Hospital, Boston, MA, United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Food Allergy Referral Centre Veneto Region, Department of Woman and Child Health, Padua University Hospital, Padua, Italy

  • Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.

  • Department of Pediatric Respiratory Medicine and Allergy,Emma Childrens Hospital/Academic Medical Center, Amsterdam, Netherlands

  • Department of Pediatric Pulmonology and Allergology, Beatrix Children's Hospital, Groningen, The Netherlands

  • Aimmune Therapeutics, Brisbane, United States

  • Mercer University School of Medicine, Macon, Georgia, United States

  • University of California, San Francisco, San Francisco, California, United States

  • Clinical Science and Education, Karolina Institutet, Sachs’ Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden

Locations

  • Spain

  • Ireland

  • Germany

  • United States

  • United Kingdom

  • Italy

  • Netherlands

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT02993107

  • NCT02635776

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved